Which hedge funds own TARS? TARSUS PHARMACEUTICALS INC, Q2 2026 13F holders
53 tracked hedge funds disclosed a position in TARS (TARSUS PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $1.1bn in total. The largest holder by portfolio weight is Deep Track Capital, LP at 3.4% of its book. 12 opened a new position this quarter: Parkman Healthcare Partners LLC, Atika Capital Management LLC, Eversept Partners, LP, Entropy Technologies, LP. 11 exited: Ally Bridge Group (NY) LLC, GordonMD Global Investments LP, Diadema Partners LP.
- 53
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 12
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 11
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $32.4m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $63.0m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $1.1bn
- Combined value Sum of the holders' reported positions in the security.
- 4.3%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Ally Bridge Group (NY) LLC | 5.6% | $5.7m |
| GordonMD Global Investments LP | 2.1% | $3.0m |
| Diadema Partners LP | 0.8% | $1.8m |
| Integral Health Asset Management, LLC | 0.7% | $14.0m |
| Braidwell LP | 0.6% | $18.6m |
| Verdad Advisers, LP | 0.5% | $444k |
| Capricorn Fund Managers Ltd | 0.3% | $1.8m |
| Persistent Asset Partners Ltd | 0.2% | $460k |
| Point72 Asset Management, L.P. | 0.03% | $15.9m |
| Caxton Associates LLP | 0.02% | $1.1m |
| Lighthouse Investment Partners, LLC | 0.01% | $231k |
Ownership over time
Who discovered TARS first? Beta
The run: Q1 2023 → Q4 2025, +551%
| Ikarian Capital, LLC high conviction | Q1 2024 | – | +8.7 pts |
| Tetragon Partners GP Ltd high conviction | Q4 2023 | – | +7.7 pts |
| Ally Bridge Group (NY) LLC high conviction | Q3 2024 | – | +3.9 pts |
| Paradigm Biocapital Advisors LP high conviction | Q1 2024 | – | +3.6 pts |
| RTW Investments, LP | Q4 2020 | 0.7% | +1.5 pts |
| Integral Health Asset Management, LLC | Q1 2024 | – | +1.3 pts |
| Cormorant Asset Management, LP | Q4 2020 | 1.2% | +0.8 pts |
| Boone Capital Management LLC | Q1 2024 | – | −1.1 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.